/
Bio-Rad Laboratories, Inc. (referred to in this report as Bio-Rad, we, us, the Company, and our ) is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, cus…
$304.36
+$3.38 (+1.12%)
EOD Jul 17, 2026
Operating margin is thin at 1.83%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue growth slowed to 0.6%, essentially flat. Margins also contracted 8.7pp. This is a business that needs a catalyst.
At 51x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Operating margin contracted 8.7pp YoY, cost discipline may be slipping.
50.6x earnings, 23.0x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.59B
▲ +0.6% YoY
Net Income (TTM)
$169M
▲ +141.2% YoY
Op. Margin
2.23%
▼ -8.7pp YoY
ROIC
0.55%
▼ -1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$357M
▲ +29.4% YoY
Op. Cash Flow (TTM)
$510M
▲ +16.9% YoY
Net Debt
-$578M
Net Cash Position
Cash & Equiv.
$1.56B
5Y CAGR: +0.3%
5Y CAGR: -4.7%
Continue Research
At a P/E of 50.6 and a price-to-free-cash-flow of 23.0, Bio-Rad Laboratories (BIO) trades above a two-stage DCF intrinsic value of about $251.06 per share, so at $304.36 the stock looks overvalued (17.5% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bio-Rad Laboratories scores 51/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $251.06 per share for BIO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $188.29. At today's $304.36, that puts the stock about 17.5% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Bio-Rad Laboratories scores 51 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 2.2% operating margin and a 0.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. BIO currently trades above its estimated intrinsic value and scores 51/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.